Trialant
Platform
Home
Studies
Other
Contact Us
Terms of Service
Privacy Policy
Toggle Sidebar
Studies
Study
JSON
Overview
Key facts that identify this study and show where it stands today.
Description
What the study is about and why it is being run, in the researchers' own words.
Conditions
The medical conditions and diseases this study investigates.
Interventions
The treatments and procedures being evaluated in this study.
Participation
Who can join this study and the criteria used to decide.
Design
How the study is designed and how its participant groups are organized.
Contacts
The people to reach with questions about this study or how to join it.
Locations
Where the study is run and whether each site is currently recruiting.
Collaborators
The organizations and people involved in this study.
Similar Studies
Other registered studies that closely resemble this one.
Workspace
Home
Studies
Collections
Views
Contact Us
Terms of Service
Privacy Policy
Sign up
NCT00076531
Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer
NCT00598312
Completed
Interventional
Phase 3
Updated Sep 8, 2010
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
NCT02234115
Completed
Interventional
Phase 3
Updated Mar 5, 2019
A Study of Leuprolide to Treat Prostate Cancer
NCT00626431
Completed
Interventional
Phase 3
Updated Jul 19, 2011
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer
NCT00128531
Completed
Interventional
Phase 3
Updated Nov 14, 2007
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
NCT03261999
Completed
Interventional
Phase 3
Updated May 4, 2020
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
NCT02212197
Completed
Interventional
Phase 2
Updated Apr 25, 2017
Clinical Trial for Prostate Cancer | NCT00076531 | Trialant
Save
Share
Completed
Interventional
Phase 3
Updated Jan 28, 2008
Clinical Trial for Prostate Cancer
ClinicalTrials.gov ID
NCT00076531
Lead Sponsor
Oakwood Laboratories, LLC
INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Jan 28, 2008
Estimated
Start Date
Dec 2003
Primary Completion Date
Nov 2004
Actual
Brief Summary
Phase III trial using an injectable for treatment of prostate cancer.
Prostate Cancer
Leuprolide Acetate for Injectable Suspension 22.5 mg
Ages Eligible for Study
Adult (18-64)
Older Adult (65+)
Sexes Eligible for Study
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
No data available
Primary Purpose
Treatment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
No locations
There are no locations for this study.
Lead Sponsor
Oakwood Laboratories, LLC
INDUSTRY